Loading company
Sol-Gel Technologies Ltd.
SLGL · Nasdaq · ·
$72.08+2.6%Sep 29 close
- 1M
- +4.8%
- 6M
- +5.2%
- 1Y
- +147.3%
- 5Y
- -20.7%
SLGL · Nasdaq · ·
$72.08+2.6%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toMar 31, 2025 | Change |
|---|---|---|---|
| Total Revenue | $591K | $1M | -42.68% |
| Profit | $11.6M | -$8M | +244.53% |
| Profit per share | $4.17 | -$0.35 | +1,295.53% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Sol-Gel Technologies Ltd. has no earnings call transcript available.
Sol-Gel is a specialized dermatology company advancing innovative therapies for rare and serious skin diseases. Its lead investigational candidate, SGT-610 (patidegib gel, 2%), is a Phase 3, orphan- and breakthrough-designated topical hedgehog inhibitor being developed for the prevention of new basal cell carcinoma (BCC) lesions in patients with Gorlin syndrome, with the potential to offer an improved safety profile relative to oral hedgehog inhibitors. Subject to regulatory approval in Gorlin syndrome, SGT-610 may also represent a future opportunity in high-frequency BCC. Sol-Gel is also advancing SGT-210, an investigational topical EGFR inhibitor for indications with significant unmet need, and has developed two FDA-approved dermatology products, TWYNEO® and EPSOLAY®.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Sol-Gel Technologies Ltd. filed on August 20, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.